Early Detection Research Network

Yildiz MALDI MS signature for lung cancer

Aliases:
This biomarker is also known as:
  • Yildiz MALDI MS signature for lung cancer,

Description…

A serum proteomic signature of seven features identified by MALDI MS has been identified. The serum signature was associated with the diagnosis of lung cancer independently of gender, smoking status, smoking pack-years, and C-reactive protein levels.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
HGNC Name:

Panel Details

No member markers defined for this panel.

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

A serum proteomic profile that discriminates lung cancer from matched controls with an overall 72.6% accuracy in a blinded test set of matched cases and controls.

Performance Comment

A serum proteomic signature of seven features in the training set reached an overall accuracy of 78%, a sensitivity of 67.4%, and a specificity of 88.9%. In the blinded test set, this signature reached an overall accuracy of 72.6 %, a sensitivity of 58%, and a specificity of 85.7%.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.